 | Countries covered: United StatesAs Kalorama publishes its second edition of this detailed report on the long term care industry and all of its segments, there is no decrease in demand or activity for everything from nursing homes, to home care, to hospices. The U.S. long care industry has experienced strong growth from 2002 through 2007 and this growth is expected to accelerate through the forecast period as the U.S. population continues to age and demand rises for long term care. Ongoing cost containment will continue to pressure both private and public managed care organizations, however, new premium-priced specialty services such as dementia care and upscale living options will create growth opportunities. |
|
| Countries covered: China, India, RussiaPharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. |
|
| This completely updated edition of Kalorama’s comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including: * Point-of-Care * Core Lab * Immunoassays * Molecular Assays * Hematology * Coagulation * Microbiology and Virology * Blood Banking * Histology and CytologyMarket size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2012. |
|
| Since the arrival of drug-eluting (called drug-eluding by some) technology a few years ago with the promise of reducing restenosis, questions abound surrounding the future of the stent market: After numerous clinical studies and mixed cost-effectiveness results, how is drug-eluding technology expected to peform in the future? What can companies do to best market this technology in the healthcare system of the US and 6 other major world markets? What are the market trends to watch that will determine growth in this field in the coming years? What companies have already established a leadership position in stents and what do start ups have to do to join them? Major World Markets for Stents and The Economics of Drug Eluding Technology, written by Kalorama Analyst Dr. Kenneth Krul, takes a hard look at these questions with economic analysis unmatched by any resource. |
|
| 2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations. Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market. |
|
| 2008 has not seen any letdown in the use of wireless technologies in healthcare settings. The clinical environment is a highly mobile one, and physicians, nurses and other clinical operators have a real need for fast information they can act upon. Wireless technologies fit healthcare well. It's therefore no surprise that hospitals are dedicating large portions of current and future budgets to IT development and wireless is likely to be among their choices. Kalorama’s Wireless in Healthcare 2008 is your guide to the still growing market for wireless healthcare applications in the United States and globally. This report contains explanations that cut through the confusion surrounding these technologies and provide readers with a total picture of wireless in healthcare. |
|
| Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well for OTC products. For the purpose of this study, Kalorama Information has divided products into five general segments: * Analgesics * Allergy, Cough, Cold, Flu Remedies * Gastrointestinal Remedies * Dermatologics * Others (including: Smoking cessation products, Sleepaids, Dental rinses, fluorides, Hair growth remedies, Diet aids) |
|
| 2008 has seen no decrease in attention on wound care products. The aging of the population and a constant demand for products that speed healing and improve outcomes drives the wound care industry. For market watchers, this makes for a dynamic market that has changed in recent years with biological developments. Kalorama Information's analyst Mary Ann Crandall has reviewed the Wound Care Industry in several editions of wound care market reports and has participated in industry panels. Kalorama Information's three-volume Wound Care Markets series examined three segments of wound care - skin ulcers, burns, surgical trauma. World Wound Care Markets 2008 takes an all-encompassing view of the wound care market. |
|
| Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena. |
|
| Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the market for prescription drugs likely to switch in the following drug categories:# Allergy and Cold# Antilipidemic Agents# Fungal Infections# Gastrointestinal Drugs# Hair Loss Treatments# Migraine Therapy# Nonsteroidal Anti-inflammatories# Oral Contraceptives# Osteoporosis and Hormone Replacement Therapies# Overactive Bladder# Sexual Dysfunction# Sleep Agents# Smoking Cessation# Viral Infections# Others |
|
| Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first successful cancer vaccine product, Merck's Gardasil, has had dramatic and surprising results. Other products also exceeded revenue expectations. The competitive dynamics have changed with merger activity, and many new products are on the way. |
|
| Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. |
|
| Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. |
|
| With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells: |
|
| Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the market for prescription drugs likely to switch in the following drug categories: |
|
| Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence cancer diagnostics? These questions and more are answered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition. Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition represents the third time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. |
|
| Novel technologies in patient monitoring are emerging to meet the increasing demands of an aging population, decreasing healthcare resources, and an emphasis on reducing hospital days. Nearly all focus on some form of ambulatory monitoring using wired or wireless technologies.It is no longer satisfactory for a system to simply monitor a patient's vital signs. Advances in remote patient monitoring include new peripherals, real-time audio and video for “face-to-face” interaction between clinicians and patients, wireless communication, systems that “sort” the vast amount of data collected in order to put it into the context of a patient’s condition, portable and ambulatory monitors, web-based access to the patient record, systems that transfer data to an electronic medical record (EMR), and full-service outsourcing that includes a clinician to evaluate data and send a report to the attending physician. |
|
| Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure. |
|
| Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. |
|
| Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. |
|
| For 12+ years, the team of Carl McEvoy and Michael Farmer have conducted exhaustive on-the-ground research in Asia, and most notabably China, interviewing lab employees and executives to obtain an accurate picture of the IVD market in China and other countries. In cooperation with Kalorama Information this report Molecular Diagnostics in China, is the definitive measure of PCR testing in China. |
|
| Catheters are among the world's oldest medical devices, but yet they are still critical part of the practice of medicine and surgery. Companies seeking opportunities in this medical device market will want to utilize Kalorama Information's World Market for Catheters. This report is a comprehensive look at the market of these critical medical devices. Which segments of catheters are growing the fastest? Which are most profitable? Who are the key players and what share do they have of the market? What are the critical issues and trends that will drive catheter sales in the future. What pitfalls do manufacturers need to be aware of? These questions and more are answered in this report. |
|
| One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. |
|
| There is over a 30 billion dollar market for technology companies who assist the healthcare industry meet its challenges. This report is a combination of 5 Kalorama Information Market research reports - over 1100 pages of material. This report details the 5 areas Kalorama thinks will be the most promising markets for technology in healthcare. |
|
|
|
| Parts of the gene expression analysis market continue to develop in a somewhat predictable manner, whereas other segments are becoming increasingly complex and volatile. The main products—microarrays and RT-PCR—continue to gain widespread acceptance and to see revenues grow rapidly. However, different products and applications are increasingly being introduced, making the market more fragmented as well as unpredictable. In terms of application, too, the landscape is shifting. Although life-science research is still the dominant application, the clinical diagnostics and prognostics market is also becoming a reality. |
|
| Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. |
|
| While insurance is the most common form of payment for healthcare services, increasingly customers are paying for their own expenses. Pharmaceutical, device and diagnostic companies, should recognize that a part of their revenues are originating directly or indirectly from out of pocket expenditures. Health care costs are high and accelerating as a result of a confluence of factors within the broader economy, as well as the health care marketplace. Unique financial services have been created to facilitate non-insurance-paid health care services, and more are expected to be created in the near term. |
|
| Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are also at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. |
|
| Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for developing regions to grab a piece of the clinical trial market. |
|
| Contract Manufacturers are finding opportunities with managers located at OEM corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. |
|
| Cell analysis is not a new laboratory procedure. Clinical diagnostics using cells and tissues is one of the oldest disciplines in laboratory medicine. Histological study of biopsy samples, the complete blood count, and the enumeration of disease-bearing cells have been used routinely for at least 60 years. In many ways, these disciplines had changed little until the 1990s. What's new, however, is the myriad of combinations of tests and technologies that come together to create a new map of cell diagnostics. |
|
| Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad — covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. |
|
| As one of the most competitive pharmaceutical markets, keeping track of the cardiovascular drug market can be a difficult undertaking. The range of therapeutic options available to physicians has expanded significantly in the past few years, and will continue to increase with a robust pipeline.
Kalorama's 2nd edition of The World Market for Cardiovascular Drugs Market is designed to steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. |
|
| For food ingredient companies willing to enter the non-food market, there is over a billion dollars of market potential awaiting them. In addition to increasing the profitability of their traditional product lines, producers of ingredients can potentially expand their markets by moving their products or byproducts into the healthcare sector, where drug producers or manufacturers of some biomedical devices could incorporate them into their products. |
|
| Abundant opportunities are available for manufacturing companies who enter the outsourcing medical device manufacturing market; but the market is competitive and information has been hard to obtain. Original equipment manufacturers (OEMs) are finding opportunities with managers located at the corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. Kalorama's OEM Contract Manufacturing in Medical Devices Series presents a total study of market for outsourcing in medical devices. It features an exhaustive three-way market segmentation: It looks at the OEM market revenues by therapeutic area, as well as by segment of device manufacturing. And it also includes revenues by the general device classifications (commodity/non-commodity). This allows those looking at this growing market to get a complete picture of the OEM market. |
|
| Retail clinics, also known as convenience clinics, represent a disruptive innovation into the U.S. health care market, which evolved from and is uniquely positioned to benefit from the health care system’s shortcomings. These clinics present a new opportunity for retail outlets to earn more revenue from rents and 'indirect' revenues from sales to the retail store as a result of a clinic visit. But there is also an opportunity for diagnostic and pharmaceutical companies to capitalize on this trend. |
|
| In five years, Kalorama Information believes the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will increase demand for drug decisions to be made at the pharmacist level. This report, Prescribing Pharmacists, a Decision Maker Emerges details the reasons behind this change and defines the roles of the new decision makers that pharmaceutical companies will have to incorporate into strategy. In the U.S. healthcare market the role of the pharmacist is changing. This report details the tremendous transformation occuring. |
|
| Drug pricing is one of the key levers that determine the profitability of a drug company. Premium pricing of a new drug helps cover the high cost of innovation and helps run a profitable enterprise. But the recent onslaught of generics, as well as shrinking government and corporate healthcare budgets, is threatening the time-tested models, leading to higher pricing pressures for pharmaceutical and biotech companies in the coming years. In this environment, executives in these companies and the consultants who service them need better information to make the most profitable decisions. |
|
| Orthopedic biomaterial products, which can be organic or synthetic in nature, are implanted into or near a bone fracture to facilitate healing or to compensate for a lack or loss of bone tissue. Biomaterials used in orthopedic surgery include autografts, allografts, xenografts, ceramics, polymers, bone growth factors and synovial fluid substitutes. Among the prominent applications for orthopedic biomaterials are surface coatings for hip prostheses, bone cements, bone defect fillers, and fracture fixation plates. |
|
| There are millions of surgical procedures performed annually worldwide and the market for wound care products and techniques is significant. In the United States alone, there are over 100,000 surgeries performed daily. Surgical and trauma wounds are, by far, the most common types of wounds addressed in the wound care area. |
|
| The aging of the population and continued advances in biotechnology drive the multi-billion dollar wound care industry globally. Besides the always-improving synthetic dressing materials, newer technologies in wound treatment include the xenogeneic tissue scaffold, bilayered human dermal substitutes, recombinant growth factors, endoscopic subfascial ligation of venous perforators, and endovascular arterial repair techniques. |
|
| The world market for OEM Contracting in the Manufacturing of Medical Devices is exploding as original equipment manufacturers are finding new opportunities with managers located at the corporate headquarters or main manufacturing/assembly operations continually reviewing manufacturing costs and looking to outsourcing for cost efficiency. |
|
| This Kalorama Information report - Clinical Nutrition Products: The World Market, represents the second time that Kalorama Information has taken a comprehensive look on the medical nutrition market in three segments:Infant Nutrition Enteral Nutrition Parenteral Nutrition |
|
| The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. While we were fortunate that, in the latter part of the 20th century, in that hepatitis was fairly well held in check, the impact of the disease on world society is still highly significant and now presenting a major crisis in public health circles. |
|
| The use of virtual reality (VR) technologies in the healthcare field is not simply a far-away future possibility. Technologies are already in place and the benefits from the application of VR are already evident in the healthcare domain. These applications provide doctors an opportunity to perform tasks in a risk-free environment, and make training accessible for a large number of students as the apprenticeship of experienced doctors is not necessary. Additionally, VR simulators allow medical professionals to remain abreast with the latest technical procedures required in the profession. |
|
| The number of procedures requiring anesthetic administration continues to climb with the growing and aging population in many regions of the world. The population of the world plays an important role in the growing incidence and prevalence of disease and will reflect positively on growth for anesthesia drugs. |
|
| The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. |
|
| In light of laboratory pressures to do more with less, laboratory managers transfer cost control onto vendors by means of a constant push for price reductions. In this commercial climate, efficient management of customer and technical service extras is critical. Expertise in managing service offerings will help companies offer service programs that are just enough to differentiate them from the competition. Service programs that offer too much may result in revenue loss. Programs that are perceived to be inadequate place the company at a competitive disadvantage. |
|
| DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work. That market has been relatively stable for the last several years, with a dominant vendor, Applied Biosystems, and relatively few changes taking place in the products or technologies. |
|
| Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. |
|
| Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that was measured after a drug was developed. Traditional studies were performed in-vivo with animals, and required 20 to 100 grams of the candidate compound for a single set of evaluations. Intake of the compound was measured, and a series of toxicity tests were performed, including LD 50 and histological examinations of target organs. These tox tests were expensive, time-consuming and were only performed on drug candidates that had already passed all other criteria to become successful drugs. These studies were high information, but low throughput estimates of a candidate drug’s toxicology. Failures were common, and expensive. The goal was to find approaches that would predict toxicology at an earlier stage, and with less cost. |
|
| The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, Over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. In addition to the basic pathology and complications of tuberculosis, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (tuberculosis patient trends) and technology. |
|
| RFID (Radio Frequency IDentification) technologies are dramatically changing many industries, but as detailed in Kalorama's market research report RFID Opportunities in Healthcare in the U.S., the greatest market for RFID is in healthcare. Hospitals, pharmaceutical companies, nursing homes, and other healthcare entities will benefit from using the technologies to keep track of inventories and patients. |
|
| Although Asia Pacific was the smallest healthcare market as of 2006, out of the three major geographic regions (US, Europe, and Asia Pacific), continued growth makes it an important ancillary market for makers of medical devices. |
|
| This study U.S. Market for Home Care Products, 5th Edition represents the fifth time Kalorama Information has investigated this growing market over the past 12 years. The U.S. market for home care products and equipment continues to post steady gains, primarily as a result of the aging population and increasing shifts of chronic care patients from hospitals to home. Serious market watchers will want to keep aware of trends in this industry, movers and shakers as well as market data. |
|
| Many in the clinical and manufacturing community have their eyes on the Physician Office Laboratory (POL) as an outlet both to improve patient compliance and outcomes and to open new market opportunities. Studies are emerging on the clinical outcomes and cost-benefit of nearer-the-patient testing, but little certain is known about POLs as a distribution channel for diagnostics products. |
|
| Molecular imaging maps the locations of specific molecules and biomaterials within living tissue. As such, it has the potential to diagnose a disease, to monitor the course of that disease, and possibly facilitate treatment. Molecular imaging has developed into a promising new strategy for the diagnosis, evaluation and treatment of disease. |
|
| This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic Threats for affected major products. Round-Up of the Key Players in each area of anti-infectives. Over 195 Tables and Figures for easy access to information and decision support tools, internal emails, memos and presentations. Discussion of Unique Issues and Emerging Trends for each antibiotic area. Market Share of Leading Competitors for each area. U.S., Europe, Japan and Rest of World market data. Product managers, marketing directors, business development executives in the pharmaceutical industry and financial and consulting company executives who invest in or serve this industry are among those who will find this report a useful resource. |
|
| This third volume of Kalorama Information’s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides: Revenue Data by Infection Type An overview of products on the market Review of products in the development pipeline Market estimates and forecasts through 2011 Market segmentation by geographic region Market share of leading suppliers Market share of leading products The report also includes statistical (epidemiologic and demographic) information for viral infections by type worldwide, with special emphasis on the United States and describes the major clinical, business, and regulatory trends shaping the global and domestic markets. The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. In addition, Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. |
|
| Cancer is the second most common cause of death in the industrialized world. At this time, treatment for cancer focuses on some combination of surgery, radiation, and chemotherapy. But over the next five years, treatment is going to dramatically change. as detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market from Kalorama Information. One of the most promising new approaches in modern cancer treatment is immunotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. Immunological and biotherapy treatments which target therapy are a fraction of total cancer treatment revenues at the current time, but will soon make up the lion’s share of the total cancer therapy market. |
|
| New biological treatments are being developed at a record place, but their potential could be compromised by significant obstacles to delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. New systems are being developed, and Kalorama's Drug Delivery Markets Series covers these new systems. |
|
| Part of a three volume series. Over one billion people suffer from fungal infections worldwide. Although athlete's foot, dandruff, vaginal yeast infection and fungal nail are the most common, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. Another has been the increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry. |
|
| This report includes all four volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal |
|
| Since the advent of LASIK nearly two decades ago, refractive vision correction remains a vibrant market impacted by technology. Kalorama's market analysis takes a look at the entire market for non-disease eye treatment procedures. Complete coverage of the vision correction market, including the correction of conditions such as myopia (nearsightedness), presbyobia (an inibility to focus), astigmatism and hyperopia or far-sightedness. |
|
| Smoking cessation is an increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and with smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. |
|
| The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities and geographic variations are shifting the sands of opportunities in diabetes care. |
|
| Contrast agents and radiopharmaceuticals have revolutionized in vivo imaging. Technical developments in contrast media and imaging techniques is combining with the trends toward both the functional and molecular understanding of disease to create a rapidly growing marketplace in these agents. |
|
| The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. |
|
| Molecular diagnostics (also known as nucleic acid testing) has emerged as a field that promises to renew technological progress in the clinical laboratory and to vastly improve patient care. Although it has been a slower than anticipated adoption in the clinical laboratory setting, molecular diagnostics has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike. |
|
| Few pharmaceutical markets will see the dramatic change that will occur in cancer therapeutics over the next four years. More than $8 billion dollars worth of new products are expected in the next four years, impacting the treatment of cancer in ways that product managers, strategic planners, business development managers and marketing executives will need to be aware of. |
|
| Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. |
|
| In the next few years, U.S. hospitals, health systems and group practices have earmarked billions for the purchase of technologies that will help them improve efficiencies and reduce costs. Electronic Medical Record (EMR) technology will certainly be among their purchases. EMR has proven it can make healthcare workflow more efficient, reduce costs, while at the same time improving the quality of patient care. Given these undisputable benefits, the 1.2 billion-dollar market for EMR is expected to grow nearly 400% in the next eight years, according to Kalorama’s experts. |
|
| Wireless technologies and healthcare are a perfect fit. The clinical environment is a highly mobile one, and physicians, nurses and other clinical operators have a real need for fast information and action. With a record of successful implementations across aspects of healthcare from patient care to sales, wireless technologies have moved from conjecture to reality. Hospitals are dedicating large portions of current and future budgets to IT development and wireless is likely to be among their choices. Given these trends, Kalorama expects the 1.7 billion dollar wireless healthcare market to grow to four times its current size by the end of the decade. |
|
| Lateral flow tests, also known as immunochromatographic strip (ICS) tests, offer dramatic benefits in the diagnostic process that point towards a robust market. LF tests reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and manufacturing. |
|
| Molecular diagnostics has emerged as a field that promises to renew technological progress in the clinical laboratory and to vastly improve patient care. Although it has been a slower than anticipated adoption in the clinical laboratory setting, molecular diagnostics (also called nucleic acid testing) has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike. |
|
| The current population of India is 1.065 billion, and with a growth rate of 1.7%, India will surpass China to become the world’s largest country around 2030. For diagnostic manufacturers, this enormous market is just now being recognized as a high-growth area as the pace of economic growth in India accelerates and modern laboratory practices become established. |
|
| With a growing elderly population, premium pricing, and growing new venues for sales, the kidney dialysis and dialysis equipment market approaches $55 billion worldwide and is expected to grow. With those revenues coming from just 1.6 million patients worldwide, kidney dialysis and equipment is among the most lucrative markets in per-capita terms. |
|
| What are the trends that are fueling a new boom in vaccine production and sales? Why is an industry so commonly associated with children finding an increasing marketplace among adult populations? What makes this class of drugs likely to grow at a faster rate than other pharmaceutical products? These are among the questions answered in Kalorama’s in-depth report, Vaccines: The World Market. |
|
| The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s World Market for Psychotherapeutic Drugs is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and drug dependence are among the conditions psychotherapeutics treat. Well-known brands such as Prozac™, Zoloft™ and Ritalin ™ have made this a $37 billion market. And according to Kalorama’s research, revenues from this area will grow more than 50% by 2010. |
|
| The oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, find a convienient form and market acceptance of new biopharmaceuticals, and tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral delivery drug market is a $35 billion industry and expected to grow as much as ten percent per year. |
|
| Since more than 11 million Americans report pain as a significant disability, there’s no question that pain management is big business for healthcare practitioners today, and one area that market watchers need to understand. When viewed globally, there is a large underserved population for pain management medications, which indicates growth in what is now a 26 billion-dollar plus industry. |
|
| In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. |
|
| Personalized medicine, the use of therapies that are targeted to the individual patient, is a reality today, thanks to a growing emphasis on biomarker research. Biomarkers are anatomic, physiologic, biochemical or molecular parameters that are associated with the presence and severity of specific diseases and illnesses. Biomarkers promise a smoother integration of diagnostics and therapeutics, and most importantly a reduction in time and cost for Phase I and II clinical trials. |
|
 | Collectively, the techniques of photon-based experimental manipulation and advanced optical imaging define the field of biophotonics. There are several key areas that are associated with biophotonics. All of these center on microscopy and related technology. The reason that this is so is that biophotonics look at biological functions at the cellular level, or even smaller. The only way that these processes can be observed is via one or another form of microscopy. |
|
| This report takes a bold look into the markets, technologies, and trends in decentralized testing with a special focus on the economics of rapid test use in critical care and emergency medicine. There is also an emphasis on early disease detection via rapid test use in clinics and public venues. The report is conservative in its predictions and offers a calculated look into the future, based on events currently taking place. |
|
| Protein biomarkers have become the hot application area for mass spectrometry (MS) and other proteomics-related technologies in the last few years. In the short term, this move towards biomarkers and clinical proteomics research has happened mainly in the drug discovery and development process. However, they also have broad abilities to generate richer information about a disease state, drug response, and/ or the relation between the two; which can be used for diagnostic, prognostic, or various other purposes in the pharmaceutical, diagnostics, and defense industries. |
|
| Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. |
|
| Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information. |
|
| With the incidence of cardiac disease on a constant growth curve, a test modality that can provide specific, inexpensive screening tools for cardiovascular disease (CVD) before the onset of symptoms, is like the proverbial "license to print money," and a large menu of tests have been developed, including serum lipids, hypercoagulation factors, enzyme and protein markers, genetic makeup, and even tests for certain viral infections. |
|
| Ultrasound, also known as sonography, is not a new imaging modality—having been around since the 1950s—but its application areas have just recently begun to expand tremendously. These new clinical applications, along with technological innovations in portability and resolution and a very favorable risk profile, have made ultrasound equipment a very robust market sector. |
|
| The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. |
|
| The global market for prescription respiratory drugs encompasses a wide variety of products that treat both common everyday respiratory illnesses as well as serious chronic conditions such as COPD. Technological developments and improved delivery methods have given many health professionals a wider range of products to treat patients with respiratory diseases and have expanded the market for respiratory pharmaceuticals. |
|
| This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. |
|
| This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. |
|
| This comprehensive evaluation of the blood industry provides an analysis of all the key market segments involved in this industry, including blood products such as: Red Blood Cells (RBCs), Immunoglobulins, Albumin, Other Plasma Products, Synthetic HBOC and PFC Agents, Recombinant Factors |
|
| This volume of the Medical Imaging Markets series explores the world of magnetic resonance imaging. This modality continues to generate growth as applications expand and new "open" systems penetrate the market. |
|
| The past 25 years have seen unprecedented advancements in the area of women’s health. A number of events have helped to bring the concerns of women’s health to the forefront of medicine but the most significant was the women’s health movement, which increased attention to women’s health issues and the shortcomings of traditional medical practice and research. |
|
| This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and g |
|
